| Location of metastasis |
| Left | 26 | 50.0% |
| Right | 25 | 48.1% |
| Midline | 1 | 1.9% |
| Frontal | 19 | 36.5% |
| Parietal | 6 | 11.5% |
| Temporal | 8 | 15.4% |
| Occipital | 6 | 11.5% |
| Frontotemporal | 1 | 1.9% |
| Temporoparietal | 1 | 1.9% |
| Parietooccipital | 1 | 1.9% |
| Cerebellum | 3 | 5.8% |
| Others (basal ganglia, insular cortex, parahippocampal, parafalcin) | 7 | 13.5% |
| GTV to PTV margin (mm) |
| 2 mm | 24 | 46.2% |
| 3 mm | 28 | 53.8% |
| Prescribed dose (Gy) |
| 15 | 1 | 1.9% |
| 17 | 2 | 3.8% |
| 18 | 17 | 32.7% |
| 20 | 30 | 57.7% |
| 24 | 2 | 3.8% |
| Prescribed isodose (%) |
| 70 | 1 | 1.9% |
| 80 | 51 | 98.1% |
| Treatment planning software |
| Oncentra Masterplan | 30 | 57.7% |
| Monaco | 17 | 32.7% |
| Radionics | 5 | 9.6% |
| Fixation technique |
| Frameless Brainlab mask | 9 | 17.3% |
| Frameless double thermoplastic mask | 38 | 73.1% |
| Invasive fixed head frame | 5 | 9.6% |
| Targeted/ immunotherapy (TT/IT) |
| BRAFi | 5 | 9.6% |
| MEKi | 1 | 1.9% |
| Anti-CTLA-4 | 4 | 7.7% |
| Anti-PD1 | 14 | 26.9% |
| BRAFi+MEKi | 6 | 11.5% |
| Anti-PD1 + Anti-CTLA-4 | 10 | 19.2% |
| Triple combination | 2 | 3.8% |
| none | 10 | 19.2% |
| Application of TT/IT |
| Before SRS (median: 9.5 days, range: 3-43 days) | 24 | 46.2% |
| Concurrent before SRS (median: 8 days, range: 3–21 days) | 21 | 40.4% |
| After SRS (median: 9 days, range: 2–97 days) | 39 | 75.0% |
| Concurrent after SRS (median: 8 days, range: 2–27 days) | 15 | 28.8% |
| Concurrent (4 weeks before or 4 weeks after SRS) | 36 | 69.2% |
